New York, NY (PRWEB) June 28, 2014
As American Medical Systems, Inc. continues to face a growing number of vaginal mesh lawsuits (http://www.transvaginalmeshlawsuithelp.com/ ) involving its transvaginal mesh products, Bernstein Liebhard LLP notes that the company is about to embark on a study to evaluate the safety of its Elevate Anterior and Apical Prolapse Repair System. According to a statement issued by Endo International PLC, the parent company of American Medical System, the 522 postmarket surveillance study for the Elevate product was mandated by the U.S. Food & Drug Administration (FDA), which has ordered all manufacturers of transvaginal mesh used to repair pelvic organ prolapse to conduct such studies in order to clarify the risks and benefits of these products.*
“Elevate products are among the American Medical Systems’ devices named in thousandsof vaginal mesh lawsuit filings. The FDA ordered that pelvic mesh manufacturers conduct these types of studies as part of the agency’s safety review of potential vaginal mesh complications,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to evaluate vaginal mesh lawsuits on behalf of women who suffered mesh erosion, chronic pain, and organ damage, allegedly due to devices marketed by American Medical Systems, as well as Boston Scientific Corp., C.R. Bard, Inc. and Ethicon, Inc.
Vaginal Mesh Complications
The FDA has been reviewing the safety of transvaginal mesh used to treat prolapse, as well as stress urinary incontinence, since October 2008, when it first alerted the public to the serious risk of vaginal mesh complications associated with these products. In July 2011, the agency issued a second alert after it received thousands of additional reports of injuries associated with these devices. In January 2012, the FDA ordered transvaginal mesh manufacturers to conduct postmarket surveillance studies, such as the one being conducted by American Medical Systems, to address specific safety and effectiveness concerns related to the use of transvaginal mesh in prolapse repair. Finally, this past April FDA announced a proposal that would reclassify mesh products used to treat prolapse as high-risk medical devices.
Court documents indicate that American Medical Systems is named a defendant in more than 1,800 vaginal mesh lawsuits that are currently pending in a federal multidistrict litigation underway in U.S. District Court, Southern District of West Virginia. These claims allege that the company’s transvaginal mesh products caused recipients to suffer a wide range of injuries, including chronic pain, mesh erosion, scarring and organ damage. Plaintiffs further allege that the devices were defectively designed and manufactured, and were sold without adequate warnings regarding their risks. (In Re American Medical Systems, Inc. - MDL No. 2325)
Jeffrey S. Grand, a partner with Bernstein Liebhard LLP, is serving on the Plaintiffs’ Steering Committee in the federal litigation or American Medical Systems vaginal mesh lawsuits. He also serves on the Committees for several other litigations in that jurisdiction, including proceedings for claims filed against Boston Scientific Corp., (MDL 2326), C.R. Bard, Inc. (MDL 2325) and Ethicon, Inc. (MDL No. 2327).
Mr. Grand is also serving as Co-Liaison Counsel in two consolidated proceedings established for C.R. Bard and Ethicon mesh lawsuits in New Jersey's Atlantic Superior Court. He was also a member of the plaintiff’s trial team for the first Ethicon trial, which ended in March with an $11 million verdict for the Plaintiff. (In re: Pelvic Mesh/Gynecare Litigation, No. 6341-10; In re: Pelvic Mesh Litigation/Bard, No. L-6339-10).
Alleged victims of serious vaginal mesh complications may be entitled to compensation for their injury-related damages. To learn more about filing a transvaginal mesh lawsuit, please visit Bernstein Liebhard LLP's website or the Firm's Facebook page: https://www.facebook.com/meshlawsuit. To obtain a free, confidential and no-obligation case review, please call 800-511-5092.
*http://www.endo.com/news-events/press-releases, Endo, June 9, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP